Fifth disease
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
16-month-month-year-old with Fifth disease ― Zombini izidlele zijika zibebomvu, ngathi uyabethwa, kwaye kuvela amaqhakuva e-maculopapular emzimbeni.
Erythema kwizidlele zombini.
References
Fifth disease , ekwabizwa ngokuba yi-erythema infectiosum, lusulelo lwentsholongwane olubangelwa yi-human parvovirus B19. Ixhaphake kakhulu ebantwaneni, ichaphazela abo baphakathi kweminyaka emi-4 ukuya kweli-14 ubudala. Iimpawu zihlala ziqala ngomkhuhlane ongephi, intloko ebuhlungu, umqala obuhlungu, kunye neemvakalelo ezinjengomkhuhlane. Abantwana banokuvela irhashalala ebomvu eyahlukileyo ebusweni obufana no- slapped cheeks , kunye nerhashalala engumzekelo emzimbeni, ezingalweni nasemilenzeni. Kubantu abadala, intlungu edibeneyo isikhalazo esiqhelekileyo, esinokubonakala kwiiveki emva kokusuleleka kokuqala. Ngokucacileyo, malunga ne-20 ukuya kwi-30% yabantu abadala abosulelwe yi-parvovirus B19 banokungabonakali naziphi na iimpawu.
Fifth disease (erythema infectiosum) is a viral infection caused by human parvovirus B19. It is more common in children than adults and usually affects children ages 4 to 14. The disease often starts with mild fever, headache, sore throat, and other flu-like symptoms. Children can also develop a bright red rash on the face that looks like “slapped cheeks”, along with a lacy or bumpy rash on the body, arms, and legs. In adults, joint aches are a common symptom. Rash and joint symptoms may develop several weeks after infection. About 20 to 30% of adults who are infected with parvovirus B19 will not have symptoms.
Fifth disease (erythema infectiosum) is a viral infection caused by human parvovirus B19. It is more common in children than adults and usually affects children ages 4 to 14. The disease often starts with mild fever, headache, sore throat, and other flu-like symptoms. Children can also develop a bright red rash on the face that looks like “slapped cheeks”, along with a lacy or bumpy rash on the body, arms, and legs. In adults, joint aches are a common symptom. Rash and joint symptoms may develop several weeks after infection. About 20 to 30% of adults who are infected with parvovirus B19 will not have symptoms.
Umngcipheko wokosulelwa parvovirus B19 ukusuka kumama ukuya kumntwana ujikeleze i-33%, malunga ne-3% yabasetyhini abosulelekileyo abafumana iingxaki kwiintsana zabo. Xa umama esosuleleka phambi kweeveki ezingama-20 ekhulelwe, amathuba okuba neengxaki ezinjengegazi kunye nokwanda kolwelo kumzimba wosana ayanda. Ukuqala ukulawula esi sifo, kufuneka sijonge ukuba isigulane siye savela kwi-parvovirus ngokuvavanya izilwa-buhlungu ezithile (IgM) . Ukuba uvavanyo alubonisi ukuvezwa kwexesha elidlulileyo kodwa lubonisa usulelo lwakutsha nje, isigulana sifuna ukujongwa ngokusondeleyo ngexesha lokukhulelwa, kubandakanywa ne-ultrasound scans rhoqo ukujonga imiba ethile yempilo yomntwana.
The rate of vertical transmission during maternal parvovirus B19 infection is estimated at 33%, with fetal complications occurring in 3% of infected women. Fetal complications comprising hemolysis, anemia, and nonimmune hydrops fetalis and fetal loss are more frequent when maternal infection occurs before 20 weeks of gestation. The first step in the management of this patient would be to obtain immunoglobulin (Ig) M and IgG titres against parvovirus to evaluate if the patient has had previous immunity against the disease. If results are negative for IgG but positive for IgM (ie, primary infection), this patient would need close obstetrical monitoring for the following weeks, including serial ultrasounds to rule out fetal anemia and hydrops fetalis.
The rate of vertical transmission during maternal parvovirus B19 infection is estimated at 33%, with fetal complications occurring in 3% of infected women. Fetal complications comprising hemolysis, anemia, and nonimmune hydrops fetalis and fetal loss are more frequent when maternal infection occurs before 20 weeks of gestation. The first step in the management of this patient would be to obtain immunoglobulin (Ig) M and IgG titres against parvovirus to evaluate if the patient has had previous immunity against the disease. If results are negative for IgG but positive for IgM (ie, primary infection), this patient would need close obstetrical monitoring for the following weeks, including serial ultrasounds to rule out fetal anemia and hydrops fetalis.
Fifth disease siqala ngeqondo eliphantsi lomkhuhlane, intloko ebuhlungu, irhashalala, kunye neempawu ezinjengomkhuhlane, njengempumlo okanye ukuvaleka. Ezi zimpawu zidlula, emva kweentsuku ezimbalwa, i-rash ibonakala. Irhashalala ebomvu eqaqambileyo idla ngokuvela ebusweni, ngakumbi ezidleleni. (kungoko igama elithi "isifo sempama esidleleni"). Ukongeza kwizidlele ezibomvu, abantwana badla ngokuba nerhashalala ebomvu, nerhabaxa kuwo wonke umzimba, kunye neengalo ezingaphezulu, umzimba, kunye nemilenze yeyona ndawo ixhaphakileyo.
Esi sifo sihlala sincinci, kodwa kubasetyhini abakhulelweyo, usulelo kwi-trimester yokuqala luye lwadibaniswa ne-hydrops fetalis, ebangela ukuphuphuma kwesisu okuzenzekelayo.
○ Unyango
Akukho unyango oluthile olufunekayo njengoko luhlala luphucula ngokuhamba kwexesha.